BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

NXTS

Nexentis Technologies Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$2000−77.8% year on year
$300000$200000$100000$0
Q4 ’20Q1 ’22Q2 ’23Q2 ’24Q3 ’25
Company filings · 10-Q filed 13 Nov 2025 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

65.1%+19.7 pp year on year
100%75%50%25%0%
Q4 ’20Q1 ’22Q2 ’23Q2 ’24Q3 ’25
Company filings · 10-Q filed 13 Nov 2025 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$8M+142.9% year on year
$10M$5M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$5M
$2M$0−$2M−$4M−$6M
Q3 ’22Q4 ’22
Company filings · 10-K filed 1 Apr 2024 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty